89694-28-0

Basic information

• Product Name: 4-AMINO-3-SULFAMOYL-BENZOIC ACID
• Synonyms: 4-AMINO-3-SULFAMOYL-BENZOIC ACID
• CAS NO: 89694-28-0
• Molecular Formula: C₇H₈N₂O₄S
• Molecular Weight: 216.21442
• Mol File: 89694-28-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 539°C at 760 mmHg
• Flash Point: 279.8°C
• Appearance: /
• Density: 1.623g/cm³
• Vapor Pressure: 1.88E-12mmHg at 25°C
• Refractive Index: 1.658
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-AMINO-3-SULFAMOYL-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-3-SULFAMOYL-BENZOIC ACID(89694-28-0)
• EPA Substance Registry System: 4-AMINO-3-SULFAMOYL-BENZOIC ACID(89694-28-0)

Safety Data

• Hazardous Substances Data: 89694-28-0(Hazardous Substances Data)

Usage

General Description

4-AMINO-3-SULFAMOYL-BENZOIC ACID, also known as 4-Aminobenzenesulfonic acid, is a chemical compound with the molecular formula C7H7NO5S. It is a derivative of sulfanilamide and belongs to the class of sulfonamide antibiotics. 4-AMINO-3-SULFAMOYL-BENZOIC ACID is commonly used in the synthesis of various pharmaceuticals and dyes, as well as in the production of water-soluble resins and polymers. It is also used as a precursor in the manufacturing of certain agricultural chemicals. Additionally, 4-AMINO-3-SULFAMOYL-BENZOIC ACID has potential applications in the field of medicine, particularly in the development of medications to combat bacterial infections.

InChI:InChI=1/C7H8N2O4S/c8-5-2-1-4(7(10)11)3-6(5)14(9,12)13/h1-3H,8H2,(H,10,11)(H2,9,12,13)

Upstream product

• 855941-97-8 4-acetylamino-toluene-3-sulfonic acid amide 
• 1205-30-7 4-chloro-3-sulphamoylbenzoic acid 
• 201224-76-2 3-oxo-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-carboxylic acid 1,1-dioxide 
• 71254-63-2 7-methyl-3-oxo-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide 
• 106-49-0 p-toluidine 
• 88-44-8 2-Amino-5-methylbenzenesulfonic acid 
• 116436-09-0 4-acetylamino-toluene-3-sulfonyl chloride 
• 74-11-3 para-chlorobenzoic acid 
• 2267-40-5 3-chlorosulfonyl-4-fluoro-benzoic acid 

Downstream Products

• 1321626-02-1 N-methyl-N-phenyl-4H-benzo[e][1,2,4]thiadiazine-7-carboxamide-1,1-dioxide 
• 1432503-72-4 methyl 2-(7-(methyl(phenyl)carbamoyl)-1,1-dioxo-4H-benzo[e][1,2,4]thiadiazin-4-yl)acetate 
• 1432503-77-9 methyl 2-(7-(methyl(phenyl)carbamoyl)-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-80-4 methyl 2-(4-bromo-2-fluorobenzyl)-4-(2-methoxy-2-oxoethyl)-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-carboxylate-1,1-dioxide 
• 1432503-81-5 methyl 2-(2-(4-bromo-2-fluorobenzyl)-1,1-dioxo-7-(piperidine-1-carbonyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-82-6 methyl 2-(2-(4-bromo-2-fluorobenzyl)-7-(morpholine-4-carbonyl)-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-83-7 methyl 2-(2-(4-bromo-2-fluorobenzyl)-7-(methyl(phenyl)carbamoyl)-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-84-8 methyl 2-(2-(4-bromo-2-fluorobenzyl)-7-(dimethylcarbamoyl)-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-86-0 methyl 2-(2-(4-bromo-2-fluorobenzyl)-7-(diethylcarbamoyl)-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-87-1 methyl 4-(2-methoxy-2-oxoethyl)-2-(2,4,5-trifluorobenzyl)-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-carboxylate-1,1-dioxide 
• 1432503-89-3 methyl 2-(1,1-dioxo-7-(piperidine-1-carbonyl)-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-91-7 methyl 2-(7-(morpholine-4-carbonyl)-1,1-dioxo-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-93-9 methyl 2-(7-(methyl(phenyl)carbamoyl)-1,1-dioxo-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-94-0 methyl 2-(7-(dimethylcarbamoyl)-1,1-dioxo-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 

Relevant articles and documents

CYCLIC INHIBITORS OF HEPATITIS B VIRUS

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

Effect on KATP channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides

The present work explored 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides diversely substituted in the 7-position. Those compounds, structurally related to previously described potassium channel openers such as the benzothiadiazine dioxide BPDZ 73, we

HYPOTENSIVE 1,2,4-BENZOTHIADIAZINES.

-